C2N Diagnostics

We are further developing and validating this test for FDA approval under FDA’s Breakthrough Devices Designation Program, with the goal of filling a major unmet medical need for a simple, widely accessible, and minimally invasive test to aid in Alzheimer’s diagnosis. We offer the test under CLIA in most of the US and a CE Mark in the European Union. Our protein biomarkers are used in numerous collaborations throughout the world with leading academic investigators and also biopharmaceutical partners. Onixt serves as the Privacy Officer for C₂N and holds a Certified Information Privacy Professional (CIPP) certification. Verghese serves as the Senior Vice President, R&D and Laboratory Operations at C₂N. Verghese is a protein and lipid biochemist with in-depth experience in basic and translational neurosciences of Alzheimer’s disease and related dementia. Sensoy’s extensive career has involved numerous market development, product launch, and commercialization efforts in multiple specialty disease states. Contois received board certification in clinical chemistry (DABCC) and is a Fellow of the American Association of Clinical Chemistry (FAACC).